Response

Affiliations

¹ Department of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK) (KGG, DS); Department of Pathology (RM) and Marie-Josée and Henry R. Kravis Center for Molecular Oncology (RM), Memorial Sloan Kettering Cancer Center, New York, NY; Integriertes Forschungs- und Behandlungszentrum (IFB) Sepsis und Sepsisfolgen, Center for Sepsis Control and Care (CSCC) University Hospital Jena, Jena Germany (AS). klaus.griewank@uk-essen.de dirk.schadendorf@uk-essen.de.
² Department of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK) (KGG, DS); Department of Pathology (RM) and Marie-Josée and Henry R. Kravis Center for Molecular Oncology (RM), Memorial Sloan Kettering Cancer Center, New York, NY; Integriertes Forschungs- und Behandlungszentrum (IFB) Sepsis und Sepsisfolgen, Center for Sepsis Control and Care (CSCC) University Hospital Jena, Jena Germany (AS).

Comment

Klaus G Griewank et al. J Natl Cancer Inst. 2015.

. 2015 Mar 9;107(4):djv051.

doi: 10.1093/jnci/djv051. Print 2015 Apr.

¹ Department of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK) (KGG, DS); Department of Pathology (RM) and Marie-Josée and Henry R. Kravis Center for Molecular Oncology (RM), Memorial Sloan Kettering Cancer Center, New York, NY; Integriertes Forschungs- und Behandlungszentrum (IFB) Sepsis und Sepsisfolgen, Center for Sepsis Control and Care (CSCC) University Hospital Jena, Jena Germany (AS). klaus.griewank@uk-essen.de dirk.schadendorf@uk-essen.de.
² Department of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK) (KGG, DS); Department of Pathology (RM) and Marie-Josée and Henry R. Kravis Center for Molecular Oncology (RM), Memorial Sloan Kettering Cancer Center, New York, NY; Integriertes Forschungs- und Behandlungszentrum (IFB) Sepsis und Sepsisfolgen, Center for Sepsis Control and Care (CSCC) University Hospital Jena, Jena Germany (AS).

No abstract available

Comment on

Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma.
Heidenreich B, Nagore E, Rachakonda PS, Garcia-Casado Z, Requena C, Traves V, Becker J, Soufir N, Hemminki K, Kumar R. Heidenreich B, et al. Nat Commun. 2014 Feb 26;5:3401. doi: 10.1038/ncomms4401. Nat Commun. 2014. PMID: 24569790
TERT promoter mutations in skin cancer: the effects of sun exposure and X-irradiation.
Pópulo H, Boaventura P, Vinagre J, Batista R, Mendes A, Caldas R, Pardal J, Azevedo F, Honavar M, Guimarães I, Manuel Lopes J, Sobrinho-Simões M, Soares P. Pópulo H, et al. J Invest Dermatol. 2014 Aug;134(8):2251-2257. doi: 10.1038/jid.2014.163. Epub 2014 Apr 1. J Invest Dermatol. 2014. PMID: 24691053
TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.
Griewank KG, Murali R, Puig-Butille JA, Schilling B, Livingstone E, Potrony M, Carrera C, Schimming T, Möller I, Schwamborn M, Sucker A, Hillen U, Badenas C, Malvehy J, Zimmer L, Scherag A, Puig S, Schadendorf D. Griewank KG, et al. J Natl Cancer Inst. 2014 Sep 13;106(9):dju246. doi: 10.1093/jnci/dju246. Print 2014 Sep. J Natl Cancer Inst. 2014. PMID: 25217772 Free PMC article.
RE: TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.
Pópulo H, Lopes JM, Sobrinho-Simões M, Soares P. Pópulo H, et al. J Natl Cancer Inst. 2015 Mar 9;107(4):djv049. doi: 10.1093/jnci/djv049. Print 2015 Apr. J Natl Cancer Inst. 2015. PMID: 25755155 No abstract available.